Immunovaccine Inc. is a biotechnology company developing high potential vaccines for human health. Immunovaccine's unique patented vaccine delivery and enhancement technology, the DepoVax™ platform, has achieved exciting results and positive pre-clinical safety data. The company’s technology has attracted multiple partnerships and generated revenues through two licenses of its technology to Pfizer Animal Health.
Immunovaccine’s most advanced product is DPX-0907, a therapeutic vaccine against ovarian, breast and prostate cancer that, in conjunction with its vaccine delivery technology, is being readied to enter Phase 1 human clinical trials. The company will pursue a fast-track regulatory strategy by taking the product through a short Phase 1 into a Phase 2 clinical trial. In addition, Immunovaccine is conducting proof of concept and pre-clinical studies for infectious disease vaccines: Pseudomonas aeruginosa, single dose pandemic influenza and Hepatitis B.
In June, the company announced its intention to go public through an RTO transaction on the TSX-V exchange and with FDA approval begin clinical trials by the end of 2009. The company continues to strengthen its vaccine pipeline through licensing and strategic partnering. With positive pre-clinical safety data and recent partnerships with LIAI, NIH, Yokohoma City University, Defense Research & Development Canada, FIT Biotech, and Immunotope Inc. the value of their Depovax™ platform is significantly enhanced.